Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

New FDA Warnings: Patients on SGLT2 Inhibitors at Risk of Acute Kidney Injury & Loperamide Abuse on the Rise

Michele B. Kaufman, PharmD, BCGP  |  July 27, 2016

GENERIC_Drugs_500x270FDA Strengthens Diabetes Drug Warning
The U.S. Food and Drug Administration (FDA) has toughened existing warnings related to the risk of acute kidney injury for sodium-glucose cotransporter-2 (SGLT2) inhibitors, canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR), which are used to treat type 2 diabetes.1 The information will be added to the product’s labeling.

Between March 29, 2013, and Oct. 19, 2015, 101 definitive cases of acute kidney injury were identified in the FDA Adverse Event Reporting System (FAERS) database. In these 101 cases, sufficient detail of acute kidney injury was present to confirm a temporal relationship with canagliflozin (n=73) and dapagliflozin (n=28). In almost all of the cases (96 out of 101, 95%) hospitalization was necessary. Of these, 22 patients required intensive care unit admission. Four deaths occurred during hospitalization; two were cardiac-related. Fifteen patients received dialysis, and of these, three had a history of chronic kidney disease or previous acute kidney injury. Six patients reported concomitant use of both an angiotensin-converting enzyme inhibitor (ACEI) and a diuretic. In the majority of cases (n=58), the time to onset of acute kidney injury occurred within the first month or less of starting the SGLT2 inhibitor.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Most patients’ conditions improved after discontinuing the agent. Eleven patients (including the four who died) did not recover. Three patients recovered with sequelae upon discontinuation, suggesting that kidney injury may not be fully reversible in some situations.

Risk factors for acute kidney injury include dehydration, hypotension and concomitant use of other drugs that can affect the kidneys (e.g., ACEI, diuretics, non-steroidal anti-inflammatory drugs [NSAIDs]). The median patient age was 57 years (range 28–79 years). Among the 84 reports that included an age, more than half were patients who were 60 years or younger. Forty-five of the 101 cases reported a change in serum creatinine or estimated glomerular filtration rate at the time of diagnosis. The median elevation of serum creatinine from baseline in 32 patients was 1.6 mg/dL.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Before initiating canagliflozin or dapagliflozin in a patient, healthcare professionals should consider factors that may predispose patients to acute kidney injury, including hypovolemia, chronic renal insufficiency, congestive heart failure and concomitant medications, such as diuretics, ACEIs, angiotensin receptor blockers and NSAIDs. Renal function should be evaluated prior to starting therapy and periodically throughout treatment. In an acute illness, fasting state, fluid loss (e.g., excessive heat exposure, gastrointestinal illness, etc.) or any state of reduced oral intake temporarily discontinue the SGLT2 inhibitor. Monitor patients for signs of acute kidney injury, and if it develops, discontinue the agent and treat appropriately.

Loperamide Abuse on the Rise
The FDA has issued a warning that taking higher than recommended doses of loperamide, both prescription and over-the-counter, can cause serious cardiac problems that can lead to death.2 These events may include arrhythmias, the likelihood of which may also increase when high doses are taken with interacting medications, such as cimetidine, clarithromycin, erythromycin, gemfibrozil, ranitidine, ritonavir and quinidine.

Individuals may take higher than recommended doses of loperamide as a result of product abuse or misuse. The majority of reported serious cardiac events have occurred in individuals who were intentionally misusing and abusing high doses of loperamide in attempts to self-treat opioid withdrawal symptoms or to achieve euphoria. The FDA continues to evaluate this safety issue and will determine if additional actions are needed.

Healthcare professionals should evaluate patients with unexplained cardiac events, including QT interval prolongation, Torsades de Pointes or other ventricular arrhythmias, syncope and cardiac arrest, as being potentially caused by patient use or abuse of loperamide. Patients who abuse loperamide often combine it with other drugs to increase its absorption and penetration across the blood brain barrier, inhibiting the metabolism of loperamide and enhancing its euphoria. If loperamide toxicity is suspected, the drug should be promptly discontinued and patients should be managed appropriately. Some cases of Torsades de Pointes may require electrical pacing or cardioversion. Advise patients to use loperamide only as prescribed and not to exceed recommended doses.


Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. U.S. Food and Drug Administration. FDA drug safety communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). 2016 Jun 14.
  2. U.S. Food and Drug Administration. FDA drug safety communication: FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium), including from abuse and misuse. 2016 Jun 7.

Page: 1 2 | Multi-Page
Share: 

Filed under:Conditions Tagged with:abusediabetesFDAFood and Drug Administrationkidneyloperamide

Related Articles

    FDA Action on Loperamide Misuse; Plus Phase 1 Trials for BAT2506 Biosimilar Begin

    November 20, 2019

    The FDA has limited the package size of some over-the-counter loperamide products to prevent its potential misuse and abuse…

    FDA Receives Reports of Loperamide Abuse

    February 14, 2018

    The FDA is seeking to limit the number of loperamide doses per package due to reports of heart-related problems and death from the misuse and abuse of the treatment…

    NSAIDs Increase MI Risk; Plus New Label Warnings for Canagliflozin

    May 29, 2017

    NSAIDs Increase Myocardial Infarction Risk According a recent meta-analysis of real-world non-steroidal anti-inflammatory drug (NSAID) use, NSAIDs may increase the risk of acute myocardial infarction (AMI). The analysis used individual patient data meta-analysis of studies from healthcare databases in Canada, Finland and the U.K. to determine the time course for risk of AMI, as well…

    Rheumatology Drug Updates: Uncertain Future for Romosozumab, Plus FDA Approves Tocilizumab for GCA

    July 20, 2017

    ajt/shutterstock.com Romosozumab’s Future Is Uncertain Romosozumab, which has the possible U.S. brand name Evenity, is awaiting approval from the FDA.1 The treatment is an investigational, injectable biologic for treating osteoporosis. It increases bone formation and bone density, reducing a patient’s risk of fractures. The manufacturer no longer expects the FDA to approve the drug this…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences